Searchable abstracts of presentations at key conferences in endocrinology

ea0022p618 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long term safety of recombinant human growth hormone (rhGH) in patients treated during childhood

Reimondo Giuseppe , Palmas Enrico , Vannelli Silvia , Bellone Jaele , Bellone Simonetta , Matarazzo Patrizia , Gasco Valentina , Borraccino Alberto , Migliaretti Giuseppe , Cavallo Franco , Ravaglia Aldo , Angeli Alberto , Aimaretti Gianluca , Terzolo Massimo

The potential side effects of the rhGH therapy have been evaluated only during treatment and the accessible databases have been developed as a post-marketing surveillance only by the Companies distributing rhGH. Aim of the present study was to evaluate health consequences (metabolic diseases and/or malignancies) in adults previously treated with rhGH during childhood. We recruited 284 patients (median age at diagnosis 12 years, range 3–17) who underwent rhGH treatment bet...

ea0016p393 | Neuroendocrinology | ECE2008

A study of the serotoninergic tone in healthy subjects and diabetic patients treated by a clinical-paedagogic approach (Group Care) or traditional care

Trento Marina , Tibaldi Paola , Balbo Marcella , Kucich Claudia , Basile Margherita , Borgo Enrica , Tomelini Michela , Passera Pietro , Giordano Roberta , Arvat Emanuela , Cavallo Franco , Porta Massimo

Background and aims: Alterations of mood and depression may be associated with type 2 diabetes (T2DM) and impaired glucose metabolism in non-diabetic people. Central serotoninergic activity may modulate glucose tolerance via neuroendocrine effectors. The serotoninergic tone was assessed by measuring the hormonal response to a selective serotonin reuptake inhibitor, citalopram, in non-diabetic subjects and patients with T2DM followed by either a traditional approach or a clinic...